Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_assertion type Assertion NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_head.
- NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_assertion description "[Embedded in this study was peripheral blood sampling for TMPRSS2-ERG and SPINK1, two genes that are believed to define prostate cancer genotypes, to assess their utility as biomarkers This study suggests that at the delivered doses, cytarabine has limited efficacy and significant myelotoxicity suggesting, it does not have a role in the treatment of docetaxel-refractory CRPC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_provenance.
- NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_assertion evidence source_evidence_literature NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_provenance.
- NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_assertion SIO_000772 22313860 NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_provenance.
- NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_assertion wasDerivedFrom befree-20140225 NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_provenance.
- NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_assertion wasGeneratedBy ECO_0000203 NP454823.RA5uinn2uI87FYTAx8kE2CXTubPlAeRb8AKsGV1MPRblg130_provenance.